Diligence memo · auto-generated · as of July 2, 2026
Organogenesis Holdings Inc.
Organogenesis Holdings Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Organogenesis Holdings Inc. operates in Biotechnology, based in CANTON.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Organogenesis Holdings Inc. has raised $130M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $130M on 2024-11-12.
Most recent recorded round closed around 2024-11-12.
Valuation (modeled)modeled
Provath models Organogenesis Holdings Inc. at approximately $1.3B (range $589M–$1.7B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.63× the median modeled value of Series D+ Biotechnology companies in 2022–2024 (75 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 20 mo ago; this sector typically re-raises about every 14 months.
Slightly overdue versus sector cadence.
Comparablesmixed
Capital scale ranks ahead of 93% of Biotechnology peers (4293 compared).
Modeled value ranks above 91% of those peers.
Closest niche peers: Areteia Therapeutics, Inc., GIO World Health Ltd, Crinetics Pharmaceuticals, Inc., 2seventy bio, Inc., Gio World Health (Europe) Sa.
Peoplefiled
18 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.